BioTime changes name to Lineage Cell Therapeutics

Workflow Solutions
Products
See more S&P Global Solutions
See More IHS Markit Solutions
Content
How We Can Help
See More
News & Insights Topics
See More
Featured Events
In PersonPolitics & Policy: Market Impacts and Mid-Year Outlooks
- 06/24/2022
- Sofitel Washington DC Lafayette Square
- 8:30 AM – 12:00 PM ET
Webinar ReplaysExpand Your Perspective: Analyzing Deal Activity & Drivers Across the Capital Markets
- 06/08/2022
- On-Demand
- 1 Hour
In Person451Nexus
- 10/03/2022
- ARIA Resort and Casino, Las Vegas, Nevada
- ARIA Resort and Casino
Platforms
Other Products
- Leveraged Commentary and Data
- Research Online

In This List

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

1 Aug, 2019

Author Annalee Armstrong
Theme Healthcare & Pharmaceuticals

BioTime Inc., a biotechnology company that focuses on developing therapies for unmet medical needs, is changing its name to Lineage Cell Therapeutics Inc.

The company's ticker will change to LCTX, effective the same day as the name change on Aug. 12, the company said July 31.

Alameda, Calif.-based BioTime said the change reflects its extensive cell therapy platform.